Marshall Wace’s Silence Therapeutics SLN Stock Holding History

Marshall Wace’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$791K	Sell	72,039 -97,577	-58%	-$686K	﹤0.01%	2318
2026 Q1	$894K	Buy	169,616 +13,936	+9%	+$76.7K	﹤0.01%	2191
2025 Q4	$947K	Buy	155,680 +72,461	+87%	+$464K	﹤0.01%	1958
2025 Q3	$432K	Sell	83,219 -92,643	-53%	-$515K	﹤0.01%	2288
2025 Q2	$1.02M	Sell	175,862 -52,556	-23%	-$225K	﹤0.01%	1835
2025 Q1	$644K	Sell	228,418 -260,471	-53%	-$1.27M	﹤0.01%	1963
2024 Q4	$3.36M	Buy	488,889 +320,472	+190%	+$4.14M	﹤0.01%	1234
2024 Q3	$3.06M	Buy	168,417 +19,020	+13%	+$354K	﹤0.01%	1205
2024 Q2	$2.84M	Buy	149,397 +10,206	+7%	+$217K	﹤0.01%	1215
2024 Q1	$3.01M	Buy	+139,191	New	+$3.03M	﹤0.01%	1195

Other funds holding SLN

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Marshall Wace's SLN Position: Q2 2026 in Review

Marshall Wace reduced its Silence Therapeutics (SLN) stake by 58% in Q2 2026, selling an estimated $686K and leaving 72,039 shares worth $791K. The position accounts for ﹤0.01% of the portfolio, ranked #2318.

Marshall Wace first reported a position in SLN in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.36M in Q4 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

Marshall Wace held 72,039 shares of Silence Therapeutics worth $791K as of Q2 2026.
Marshall Wace sold 97,577 Silence Therapeutics shares in Q2 2026, an estimated $686K.
Silence Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2318 holding.
Marshall Wace first reported a position in Silence Therapeutics in Q1 2024 and has held it in 10 quarters since.
Marshall Wace's Silence Therapeutics position peaked at $3.36M in Q4 2024.
72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.